ACER THERAPEUTICS INC.: 10-Q filed 2014-08-14
What ACER THERAPEUTICS INC. reported in its quarterly report filed 2014-08-14 (fiscal Q2 2014): 22 published measures, 53 facts as tagged in accession 0001157523-14-003490.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-08-14
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001157523-14-003490 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACER THERAPEUTICS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 19,093,087 | USD | |
| At 2013-12-31 | 26,239,808 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 5,539,707 | USD | |
| At 2013-12-31 | 5,662,534 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 13,553,380 | USD | |
| At 2013-12-31 | 20,577,274 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 16,214,690 | USD | |
| At 2013-12-31 | 23,644,542 | USD | |
| At 2013-06-30 | 5,028,280 | USD | |
| At 2012-12-31 | 592,004 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -4,163,259 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -7,818,833 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -2,996,430 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -7,173,912 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 127,222 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 22,894 | USD | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,234,826 | USD | |
| At 2013-12-31 | 1,295,024 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | -4,167,549 | USD | 91 |
| 2014-01-01 to 2014-06-30 | -7,828,317 | USD | 181 |
| 2013-04-01 to 2013-06-30 | -2,713,696 | USD | 91 |
| 2013-01-01 to 2013-06-30 | -5,295,708 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 17,696,216 | USD | |
| At 2013-12-31 | 24,767,118 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-04-01 to 2013-06-30 | 285,800 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,921,054 | USD | 181 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 3,693,587 | USD | |
| At 2013-12-31 | 3,324,493 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 835,570 | USD | |
| At 2013-12-31 | 696,155 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 3,409,210 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 6,220,349 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 2,223,030 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 3,844,396 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 27,661,675 | shares | |
| At 2013-12-31 | 27,546,058 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 147,363,541 | USD | |
| At 2013-12-31 | 146,569,758 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,905,854 | USD | |
| At 2013-12-31 | 1,718,477 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 162,045 | USD | |
| At 2013-12-31 | 177,666 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-06-30 | 1,627,271 | USD | |
| At 2013-12-31 | 1,232,990 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-04-01 to 2014-06-30 | 967,367 | USD | 91 |
| 2014-01-01 to 2014-06-30 | 2,070,247 | USD | 181 |
| 2013-04-01 to 2013-06-30 | 750,605 | USD | 91 |
| 2013-01-01 to 2013-06-30 | 1,853,040 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 194,244 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 167,209 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-06-30 | 37,910 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-06-30 | 132,591 | USD | 181 |
| 2013-01-01 to 2013-06-30 | 635,368 | USD | 181 |
Inspect the source
- Entity
- ACER THERAPEUTICS INC. / CIK 0001069308
- Captured
- SEC response SHA-256
d41ecd9c66d537efeeb403c8604fe32734f808b5d83b00a9acc9f0ba72164b38
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001069308.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))